中国全科医学2024,Vol.27Issue(24) :3031-3037.DOI:10.12114/j.issn.1007-9572.2023.0533

短链脂肪酸在2型糖尿病中的作用研究进展

Advances in the Role of Short-chain Fatty Acids in Type 2 Diabetes

姜荣生 张龙 管其凡 张静 吴元丰 刘明军
中国全科医学2024,Vol.27Issue(24) :3031-3037.DOI:10.12114/j.issn.1007-9572.2023.0533

短链脂肪酸在2型糖尿病中的作用研究进展

Advances in the Role of Short-chain Fatty Acids in Type 2 Diabetes

姜荣生 1张龙 1管其凡 1张静 1吴元丰 1刘明军1
扫码查看

作者信息

  • 1. 130117 吉林省长春市,长春中医药大学针灸推拿学院
  • 折叠

摘要

短链脂肪酸(SCFAs)在肠道微生物群调控宿主代谢中起到了主要介导作用,且与2型糖尿病(T2DM)密切相关,可改善T2DM患者的血糖、体质量和血脂指标.尽管有学者认为SCFAs有望成为T2DM的新型治疗靶点,但目前尚未有相关综述.本文总结了短链脂肪酸的生物学特性,讨论了SCFAs调节食欲、炎症、胰岛β细胞、脂质代谢与肝脏糖原代谢的证据,进一步明确调控SCFAs在T2DM中的作用及其研究进展,探讨了调控SCFAs治疗T2DM的潜力.

Abstract

Short-chain fatty acids(SCFAs)play a major mediating role in gut microbiota regulation of host metabolism and are strongly associated with type 2 diabetes mellitus(T2DM),which improves glycemic,body weight,and lipid indices in T2DM patients.Although it has been suggested that SCFAs are expected to be novel therapeutic targets for T2DM,no review has been conducted.Therefore,this paper summarizes the biological properties of SCFAs,discusses the evidence that SCFAs regulate appetite,inflammation,pancreatic β-cells,lipid metabolism and hepatic glycogen metabolism,further clarifies the progress of research on regulating the role of SCFAs in T2DM and their mechanisms,and explores the potential of regulating SCFAs for the treatment of T2DM.

关键词

糖尿病,2型/短链脂肪酸/胃肠道微生物组/代谢/研究进展

Key words

Diabetes mellitus,type 2/Short chain fatty acid/Gastrointestinal microbiome/Metabolism/Research progress

引用本文复制引用

基金项目

国家自然科学基金(82174525)

吉林省科技发展计划(YDZJ202201ZYTS195)

出版年

2024
中国全科医学
中国医院协会

中国全科医学

CSTPCD北大核心
影响因子:2.04
ISSN:1007-9572
被引量1
参考文献量78
段落导航相关论文